Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Capecitabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    555 result(s) found for: Capecitabine. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000758-37 Sponsor Protocol Number: NO18517 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
    Medical condition: High Grade Glioma Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004465-27 Sponsor Protocol Number: COCA Start Date*: 2018-02-01
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with colorectal cancer or other solid tumours ' the COCA s...
    Medical condition: Colorectal carcinoma or other solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000221-31 Sponsor Protocol Number: DS8201-A-U301 Start Date*: 2019-02-06
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER...
    Medical condition: Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Ongoing) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001045-12 Sponsor Protocol Number: NO21125 Start Date*: 2016-07-20
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas.
    Medical condition: Intrinsic Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-008476-14 Sponsor Protocol Number: CAP001 Start Date*: 2009-08-07
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Pharmacokinetic Study of Adjuvant Capecitabine in Patients who have undergone Proximal Pancreatico-Duodenectomy for Resection of Pancreatic Adenocarcinoma
    Medical condition: For patients who have undergone proximal pancreatico-duodenectomy for resection of pancreatic adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009908-39 Sponsor Protocol Number: CAP002 Start Date*: 2009-07-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A pharmacokinetic study of capecitabine in patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomach
    Medical condition: Patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomach
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002801-22 Sponsor Protocol Number: X100 Start Date*: 2006-08-18
    Sponsor Name:The Royal Marsden NHSF Trust
    Full Title: Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX)
    Medical condition: relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6 10026662
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004003-12 Sponsor Protocol Number: FluorouracilCapecitabine001 Start Date*: 2020-01-14
    Sponsor Name:Jessa Hospital
    Full Title: Implementation of pre-emptive geno- and phenotyping in 5-FU- or capecitabine-treated patients with the aim of reducing toxicity
    Medical condition: Gastro-intestinal cancers: stomach, pancreas, colon, rectum, anal tumors, esophagus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004492-38 Sponsor Protocol Number: PUMA-NER-1301 Start Date*: 2013-07-30
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastati...
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) IT (Completed) BE (Completed) CZ (Completed) ES (Completed) AT (Completed) SE (Completed) IE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011217-24 Sponsor Protocol Number: E7389-E044-203 Start Date*: 2009-12-03
    Sponsor Name:Eisai Ltd
    Full Title: A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine
    Medical condition: Phase 1 - Advanced and/or metastatic cancer Phase 2 - Advanced and/or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027477 Metastatic carcinoma LLT
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002080-93 Sponsor Protocol Number: EGF103659 Start Date*: 2006-10-06
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
    Medical condition: ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NL (Completed) BE (Completed) PT (Completed) CZ (Completed) SK (Completed) IS (Completed) DE (Completed) AT (Completed) EE (Completed) GR (Completed) DK (Completed) FI (Completed) SE (Completed) IT (Prematurely Ended) MT (Completed) SI (Completed) GB (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002861-37 Sponsor Protocol Number: EURABEL-2 Start Date*: 2007-01-19
    Sponsor Name:Ziekenhuisapotheek Meppel-Hoogeveen
    Full Title: Evaluation of the oral uracil loading test as a sensitive, simple and cheap method to detect DPD deficiency.
    Medical condition: Extreme toxicity during of after chemotherapy with a 5-fluorouracil of capecitabine containing regimen for colorectal, breast or head and neck cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002715-24 Sponsor Protocol Number: TARGET1 Start Date*: 2005-09-29
    Sponsor Name:Royal Marsden Hospital
    Full Title: TARGET Trial: A Phase I-II dose finding and early efficacy study of combination therapy with erlotinib (tarceva), gemcitabine, bevacizumab (avastin) and capecitabine in advanced pancreatic cancer.
    Medical condition: Advanced Pancreatic Cancer - either locally advanced disease not amenable to curative resection and metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033606 Pancreatic cancer non-resectable LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000412-82 Sponsor Protocol Number: M07PFU Start Date*: 2007-05-07
    Sponsor Name:NKI-AVL
    Full Title: PHARMACOGENOMIC AND PHARMACOKINETIC SAFETY AND COST-SAVING ANALYSIS IN PATIENTS TREATED WITH FLUOROPYRIMIDINES
    Medical condition: cancer, treated with capecitabine or 5-FU in DPD-deficient individuals
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003646-34 Sponsor Protocol Number: LT-COX-2.001 Start Date*: 2005-10-10
    Sponsor Name:Klaipeda hospital
    Full Title: COX-2 alteration in advanced colon cancer treated with capecitabine versus 5-fluorouracil and calcium folinate (Mayo regimen) combination
    Medical condition: III stage (Dukes' stage) colon cancer patients who underwent surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001457-10 Sponsor Protocol Number: D1532C00011 Start Date*: 2006-06-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda™ ) in Patients with Colorectal Cancer who have Failed Two Prior Chemotherapeutic Regimens.
    Medical condition: metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003502-13 Sponsor Protocol Number: Ca.So. Start Date*: 2018-01-19
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/So...
    Medical condition: advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024662 Liver cell carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003187-32 Sponsor Protocol Number: etoxel-01-2005 Start Date*: 2005-12-19
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinoma
    Medical condition: Advanced Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004167-25 Sponsor Protocol Number: NKI-AVLM22TGA Start Date*: 2023-05-04
    Sponsor Name:Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hosp
    Full Title: Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with peritoneal metastases
    Medical condition: Advanced colorectal cancer with peritoneal metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004059-22 Sponsor Protocol Number: CL3-95005-006 Start Date*: 2018-06-01
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of pati...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) SE (Ongoing) AT (Completed) ES (Ongoing) DK (Ongoing) LT (Ongoing) NL (Completed) LV (Ongoing) SK (Ongoing) CZ (Ongoing) HU (Completed) DE (Completed) PL (Ongoing) PT (Completed) BG (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA